Veradermics Launches Late-Stage Trial for First Oral Treatment for Female Pattern Hair Loss
A potential breakthrough is on the horizon for women experiencing female pattern hair loss (FPHL), as Veradermics, Inc. has initiated a phase 2/3 clinical trial evaluating VDPHL01, an extended-release oral formulation of minoxidil. This marks the first late-stage US clinical trial specifically targeting FPHL with an oral treatment, addressing a significant gap in care for a condition affecting millions.
The trial, announced on November 18, 2025, represents a major step forward in a field that has seen limited therapeutic innovation for decades. “For too long, women have shouldered a significant physical and emotional burden of hair loss,” stated a leading dermatologist involved in the study. “I’ve seen their distress first-hand – managing their confidence, anxiety and shift in self-identity – while cycling through sub-optimal treatments.”
A Comprehensive Clinical Program
The newly launched, double-blind, randomized trial (NCT07146022) is part of a broader phase 3 program encompassing three registration-directed studies in both women and men with pattern hair loss. Veradermics plans to enroll over 500 women, making it one of the most extensive clinical investigations in the history of FPHL. This commitment is particularly noteworthy given that women represent 85% of the US aesthetics market and the majority of hair supplement users, yet have faced a 30-year drought of FDA-approved prescription therapies for FPHL.
In addition to the phase 2/3 program, the company is conducting an open-label, multi-dose phase 2 trial for individuals with mild-to-moderate pattern hair loss who are not currently undergoing other active treatments. The female cohort (n=22) has completed enrollment, with dosing ongoing over a 12-month period. Primary endpoints will focus on non-vellus target area hair count and patient-reported outcomes regarding perceived effectiveness. Preliminary findings from the male cohort have shown encouraging early visible and measurable improvements as soon as two months after treatment initiation, with full results from both cohorts anticipated in 2026.
Addressing a Significant Unmet Need
An estimated 80 million people in the United States, including 30 million women, are affected by pattern hair loss. This condition often carries a substantial psychosocial impact, including depression, low self-esteem, and social withdrawal. Currently, the only FDA-approved therapy for FPHL is topical 5% minoxidil, which suffers from limited efficacy and adherence issues, with up to 86% of users discontinuing treatment due to inconvenience and cosmetic concerns. The global market for pattern hair loss treatments is projected to reach $30 billion by 2028, highlighting the demand for more effective solutions. Existing alternatives, such as nutraceuticals and off-label medications, often lack consistent clinical benefit or have variable safety profiles.
VDPHL01: A Novel Approach to Minoxidil Delivery
VDPHL01 aims to overcome the limitations of existing treatments as a non-hormonal, extended-release oral minoxidil tablet. The formulation is designed to optimize systemic exposure while minimizing peak-related adverse effects commonly associated with immediate-release minoxidil. Utilizing a proprietary gel-matrix delivery system, VDPHL01 maintains sustained plasma concentrations linked to hair growth while avoiding high peaks that could potentially lead to cardiovascular side effects. Promising results in patients with androgenetic alopecia were presented at the European Academy of Dermatology and Venereology (EADV) Congress in September 2025.
If approved, VDPHL01 would be the first prescription oral therapy specifically for women with pattern hair loss. “Female pattern hair loss has many nuances – from differences in symptoms and presentation to underlying causes – and little has been done to advance research or understanding in this area,” explained Reid Waldman, MD, CEO of Veradermics. “At Veradermics, we are committed to bringing scientific rigor and therapeutic innovation to an aesthetic condition where women have been underrepresented and at times even excluded from early drug development. We are incredibly excited about the potential of VDPHL01 to close the long-standing gap in care for both women and men.”
References:
- Veradermics Advances VDPHL01 in Phase 2/3 Clinical Trial for Female Pattern Hair Loss, Marking a Milestone in the Development of the Potential First-Ever Oral Prescription Treatment for Women. News release. Business Wire. Published November 18, 2025. Accessed November 18, 2025. https://www.businesswire.com/news/home/20251118317254/en/Veradermics-Advances-VDPHL01-in-Phase-23-Clinical-Trial-for-Female-Pattern-Hair-Loss-Marking-a-Milestone-in-the-Development-of-the-Potential-First-Ever-Oral-Prescription-Treatment-for-Women
- Shapiro J, Senna M, Muller-Ramos P, Lo Sicco K. Comparative efficacy of an investigational oral minoxidil extended-release tablet (VDPHL01) versus existing minoxidil formulations in androgenetic alopecia: a blinded retrospective IGA analysis. Presented at: European Academy of Dermatology and Venereology Congress 2025; September 17-20, 2025; Paris, France.
